Portfolio Companies

New Rhein Funds I, II and III have invested over $165 million across 11 companies throughout multiple therapeutic areas and stages of development. Our diverse portfolio includes novel medications for the treatment of asthma & COPD, Benign Prostatic Hyperplasia (BPH), migraine, Pulmonary Arterial Hypertension (PAH), Nerve Repair, and Metabolic disease.